ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
ADC Therapeutics收到紐約證券交易所不遵守持續上市標準的通知
ADC Therapeutics SA (NYSE:ADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that the Company is not in compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual, which requires listed companies to maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period.
ADC Therapeutics SA（紐約證券交易所代碼：ADCT）今天宣佈，它於2023年10月10日收到紐約證券交易所（NYSE）的通知，稱該公司不符合《紐約證券交易所上市公司手冊》第802.01C節規定的持續上市最低價格標準，該標準要求上市公司在連續30個交易日內將平均收盤價維持在至少1.00美元。
資訊熱榜
更新時間